Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Acceleron Pharma Inc.
  6. Company
    XLRN   US00434H1086

ACCELERON PHARMA INC.

(XLRN)
End-of-day quote Nasdaq  -  11-18
178.75 USD   -0.52%
2021GLOBAL MARKETS LIVE : Airbus, BP, Merck, Pfizer, Meta...
2021Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
DJ
2021ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index
CI
SummaryQuotesChartsNewsRatingsCompany 
Business Summary
Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC). It generates multiple Fc-fusion protein ligand traps, IntelliTrap platform technology and a pipeline of clinical and preclinical therapeutic candidates targeting mechanisms underlying serious and rare diseases.
Managers
Name Title Age Since
Rita Karachun President 60 -
Kevin McLaughlin Chief Financial Officer & Senior Vice President 64 -
Ravindra Kumar Chief Scientific Officer & Senior Vice President 61 2016
Lisa Wyman Vice President-Operations - 2019
Aaron Rosenberg Treasurer & Senior Vice President - -
Jon Filderman Secretary - -
Jerome Mychalowych Vice President-Tax - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,155,826 53,794,685 88.0% 0 0.0% 88.0%
Company contact information
Acceleron Pharma, Inc.
128 Sidney Street
Cambridge, MA 02139

Phone : +1.617.649.9200
Fax : +1.617.649.9988
Web : http://acceleronpharma.com/
Brand Portfolio
In partnership withAllbrands.markets
More brands of Acceleron Pharma Inc.
Analysis
Merck to buy Acceleron for about $11.5 billion in rare disease drug push
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ACCELERON PHARMA INC.0.00%10 932
GILEAD SCIENCES, INC.-14.10%78 232
REGENERON PHARMACEUTICALS, INC.2.22%69 552
VERTEX PHARMACEUTICALS12.35%63 100
WUXI APPTEC CO., LTD.-14.92%43 023
BIONTECH SE-38.39%38 601
GENMAB A/S-22.70%18 636
ARGENX SE-5.49%16 947
BEIGENE, LTD.-50.96%13 709
NEUROCRINE BIOSCIENCES, INC.-1.23%8 040
EXELIXIS, INC.9.85%6 429
LEGEND BIOTECH CORPORATION-15.55%6 070
SAREPTA THERAPEUTICS, INC.-26.74%5 772
INTRA-CELLULAR THERAPIES, INC.12.92%5 575
HALOZYME THERAPEUTICS, INC.0.52%5 569
BIOCON LIMITED-10.56%5 008
ASCENDIS PHARMA A/S-38.21%4 638
MARAVAI LIFESCIENCES HOLDINGS, INC.-19.95%4 412
PHARMAESSENTIA CORPORATION33.45%3 685
ULTRAGENYX PHARMACEUTICAL INC.-38.79%3 599
CYTOKINETICS, INCORPORATED-7.83%3 598
Connections : Acceleron Pharma Inc.